The Zacks Analyst Blog Highlights: Celgene, Gilead, Amgen, Biogen and Alexion - KXNet.com - Bismarck/Minot/Williston/Dickinson-KXNEWS,ND

The Zacks Analyst Blog Highlights: Celgene, Gilead, Amgen, Biogen and Alexion

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Zacks Investment Research, Inc.

CHICAGO, May 1, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Celgene (Nasdaq:CELG-Free Report), Gilead (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Biogen (Nasdaq:BIIB-Free Report) and Alexion (Nasdaq:ALXN-Free Report).

Zacks Investment Research, Inc., www.zacks.com.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

 

Last week, several major biotech companies -- Celgene (Nasdaq:CELG-Free Report), Gilead (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Biogen (Nasdaq:BIIB-Free Report) and Alexion (Nasdaq:ALXN-Free Report) -- reported first quarter results.

 

The clear winner was Gilead with its hepatitis C virus (HCV) treatment, Sovaldi bringing in sales of $2.3 billion in its first full quarter on the market. Although a lot has been said about the drug's high price, the sales figures show the high acceptance level thanks to its strong efficacy profile. Earnings were way above expectations. The only disappointing part was the company not raising its guidance or providing specific guidance for Sovaldi sales.

 

Biogen also came out with impressive sales on its oral multiple sclerosis drug, Tecfidera, and raised its guidance for 2014. Alexion topped expectations thanks to Soliris and upped its earnings guidance for 2014.

 

Meanwhile, Celgene's earnings were slightly better-than-expected but revenues fell short of expectations. The company maintained its guidance and announced an acquisition deal which will add a late-stage Crohn's disease experimental drug to its portfolio.

 

Amgen's first quarter results were disappointing with the company reporting a decline in earnings. Although revenues increased from the year-ago period, they were well short of expectations. Revenues also fell on a sequential basis with most products recording a sequential decline.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

 

Get the full Report on CELG - FREE

Get the full Report on GILD - FREE

Get the full Report on AMGN - FREE

Get the full Report on BIIB - FREE

Get the full Report on ALXN - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

 

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
General information or questions:
kxinfo@kxnet.com

News:
Bismarck:
Phone: 701-223-9197
News Fax: 701-223-1985

News:
Minot:
Phone: 701-852-2104
News Fax: 701-838-1050
All content © Copyright 2000 - 2014 WorldNow and KXNET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.